Ahead of its earnings after the closing bell, cannabis-producer Aurora says it has shipped a batch of cannabis oil to the U.K. The company also says that it was one of the first Canadian licensed pot producers to export product to the U.K., which allows specialist doctors to issue prescriptions for cannabis-based medicine.
Closer to home, Aurora and competitor Canopy have established a complex scheme that gives them the ability to acquire a majority stake in several U.S. companies that they once owned, should the federal government legalize marijuana.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
The 50-day moving average for ACB moved above the 200-day moving average on September 30, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 57 of 66 cases where ACB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on September 21, 2026. You may want to consider a long position or call options on ACB as a result. In 81 of 92 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
Following a +14.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where ACB advanced for three days, in 176 of 231 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.
The Aroon Indicator entered an Uptrend today. In 61 of 95 cases where ACB Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Moving Average Convergence Divergence Histogram (MACD) for ACB turned negative on September 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 40 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ACB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
ACB broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Seasonality Score of 39 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. ACB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 49 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.695) is normal, around the industry mean (43.873). P/E Ratio (19.440) is within average values for comparable stocks, (141.710). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.984) is also within normal values, averaging (178.797).
The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ACB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 84, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a licensed producer of medical marijuana in Canada
Industry PharmaceuticalsGeneric